US Prescribers Embrace Oncology Biosimilars; How Will Humira Follow-Ons Fare?
Executive Summary
Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.
You may also be interested in...
Can Biosimilars Compete With ‘Unbranded Biologics’ In The US Market?
Biologics with their brand name dropped from the label could become the alternative to an ‘authorized biosimilar,’ which is not allowed under the law.
Roche: US Biosimilar Impact Worse Than Expected And ‘Pretty Much Like Europe’
Roche was forced to revise its forecasts for biosimilar competition last year, but even an upward revision of CHF1bn fell short as biosimilar sponsors stole a march in the US at a level that caught the originator by surprise.
US Biosimilar Spending Poised For Substantial Growth By 2024, IQVIA Says
Biosimilar spending in the US is expected to increase from $5.2bn in 2019 to $27bn in 2024, driven by increased penetration and new biosimilar entries, including for Humira, according to an IQVIA report.